Research Lab (UPMC-INSERM UMR-S938)

Welcome!

Our team associates physiologists, cell biologists, biochemists, and clinicians devoted to the physiological and biological understanding of osteoarthritis, particularly by exploring the role of metabolism, inflammation, mechanical stress and bone/cartilage communication in this disease.

Research brief

 A few years ago, we started to look at the role of tissue interactions in osteoarthritis (OA),a disease initially considered as cartilage-driven. OA is a much more complex disease, with inflammatory mediators released by cartilage, bone and synovium interacting into the joint. Because obesity is a risk factor for OA in non-weight-bearing joints such as the hand, adipokines were suggested to play a role in OA. Starting from our work on the involvement of adipokines in OA, we address the hypothesis of a role of metabolic syndrome in OA progression. Metabolic syndrome-associated OA (MetS-OA) has recently been highlighted among the overall group of OA phenotypes, but the molecular mechanisms underlying the role of MetS in cartilage degradation has been poorly studied. Indeed, studies suggest that OA structural progression may result from altered communication between subchondral bone cells (e.g., osteoblasts, osteocytes) and cartilage cells (chondrocytes) and atheromatous vascular disease of subchondral bone.

In parallel, we have launched a cohort of patients (DIGICOD cohort) suffering from hand OA going to be followed at least 6 years in order to collect biological, imaging and clincal data to better understand the pathophysiology and the prognosis of this disease.

Four main projects are currently under investigation:

1 – Identify novel soluble mediators secreted by activated bone cells and acting on chondrocytes.

2 – Effect of hypertrophic differentiation of chondrocytes on remodelling of the osteochondral junction.

3 – Role of metabolic syndrome in OA beyond obesity.

4 – Preclinical/clinical validation of our in vitro or ex vivo discoveries.

Methodologies used

– Primary culture of articular chondrocytes (mouse, human) and costal chondrocytes (mouse), of murine osteoblasts (membrane 3D) and of human synoviocytes

– Control of chondrocyte phenotype (hypertrophic differentiation and fibroblastic dedifferentiation)

– Application of mechanical stress (cartilage explants and bone), Flexercell apparatus

– Bone/cartilage communication model (murine)

– Mesenchymal stem cells (from rat bone marrow)

-Cellular analysis (Western-blot, proteolytic activity, ELISA, qRT-PCR, ARN interference, immunocytology)

– Tissue analysis (histology paraffin, immunohistochemistry)

– Experimental model for Osteoarthritis (Mouse)

– Experimental model of tendon repair (Rat)

Research Unit

INSERM UMRS-938 (http://www.cdr-saint-antoine.fr/fr/)

Faculté de Médecine Pierre & Marie Curie Paris VI

Hôpital Saint-Antoine, AP-HP

184 rue du faubourg Saint-Antoine, 75012 PARIS, FRANCE

tel. +33 1 49 28 25 20

Fax. +33 1 49 28 25 13

francis.berenbaum@aphp.fr

Team Organisation

Chef d’équipe / Team leader

  • Francis Berenbaum (Professor at Pierre & Marie Curie University, Rheumatologist at AP-HP Saint-Antoine hospital)

Chercheurs / Established researchers

  • Xavier Houard (Assistant Professor UPMC)
  • Claire Jacques (Assistant Professor UPMC)
  • Geoffroy Nourissat (Orthopedist)
  • Jérémie Sellam (Professor UPMC and AP-HP)

ITA / Technicians – Engineers

  • Audrey Pigenet (T UPMC)
  • Danièle Citadelle (T UPMC)
  • Laure Sudre (IR)

Post-doctoral scientific and clinical fellows

  • Maria-Louisa Perez Lozano
  • Natalia Zapata Linares

Doctoral fellows

  • Marion Millerand
  • Florent Eymard
  • Sandy Van Eegher
  • Alice Courties
j

Team Publications

2017

2016

  1. van der Kraan PM, Berenbaum F, Blanco FJ, Cosimo de B, Lafeber F, Hauge E, et al. Translation of clinical problems in osteoarthritis into pathophysiological research goals. RMD open. 2016;2(1):e000224.

     

  2. Tomi AL, Sellam J, Lacombe K, Fellahi S, Sebire M, Rey-Jouvin C, et al. Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study. Annals of the rheumatic diseases. 2016;75(12):2101-7.

     

  3. Teboul-Core S, Rey-Jouvin C, Miquel A, Vatier C, Capeau J, Robert JJ, et al. Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases. Skeletal radiology. 2016;45(11):1495-506.

  4. Souberbielle JC, Benhamou CL, Cortet B, Rousiere M, Roux C, Abitbol V, et al. French law: what about a reasoned reimbursement of serum vitamin D assays? Geriatrie et psychologie neuropsychiatrie du vieillissement. 2016.
     
  5. Siebuhr AS, Bay-Jensen AC, Jordan JM, Kjelgaard-Petersen CF, Christiansen C, Abramson SB, et al. Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment? Scandinavian journal of rheumatology. 2016;45(2):87-98.
     
  6. Sellam J, Lacombe K, Tomi AL, Haugen IK, Felson DT, Fellahi S, et al. Response to: ‘Does the prevalence of radiographic hand osteoarthritis in patients with HIV-1 infection increase or not?’ by Luo et al. Annals of the rheumatic diseases. 2016;75(8):e52.

  7. Ornetti P, Nourissat G, Berenbaum F, Sellam J, Richette P, Chevalier X. Does platelet-rich plasma have a role in the treatment of osteoarthritis? Joint, bone, spine : revue du rhumatisme. 2016;83(1):31-6.

  8. Nikiphorou E, Studenic P, Ammitzboll CG, Canavan M, Jani M, Ospelt C, et al. Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET). Annals of the rheumatic diseases. 2016.

  9. Nefla M, Holzinger D, Berenbaum F, Jacques C. The danger from within: alarmins in arthritis. Nature reviews Rheumatology. 2016;12(11):669-83.

  10. Krams T, Ruyssen-Witrand A, Nigon D, Degboe Y, Tobon G, Fautrel B, et al. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. Joint, bone, spine : revue du rhumatisme. 2016;83(5):511-5.

  11. Hochberg MC, Martel-Pelletier J, Monfort J, Moller I, Castillo JR, Arden N, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the rheumatic diseases. 2016;75(1):37-44.

  12. Gossec L, Baillet A, Dadoun S, Daien C, Berenbaum F, Dernis E, et al. Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. Joint, bone, spine : revue du rhumatisme. 2016;83(5):501-9.

  13. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liote F, Meyer A, et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clinical rheumatology. 2016;35(4):857-61.

  14. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liote F, Fautrel B, et al. Body mass index and response to abatacept in rheumatoid arthritis. European journal of clinical investigation. 2016;46(12):1048-52.

  15. Fagnani F, Pham T, Claudepierre P, Berenbaum F, De Chalus T, Saadoun C, et al. Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France. Journal of medical economics. 2016;19(8):812-21.

  16. Edwards MH, Parsons C, Bruyere O, Petit Dop F, Chapurlat R, Roemer FW, et al. High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. The Journal of rheumatology. 2016;43(3):657-65.

  17. Berenbaum F, Meng QJ. The brain-joint axis in osteoarthritis: nerves, circadian clocks and beyond. Nature reviews Rheumatology. 2016;12(9):508-16.

  18. Berenbaum F, Griffin TM, Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis & rheumatology (Hoboken, NJ). 2016.

2015

  1. Berenbaum F, Griffin TM, Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis & rheumatology (Hoboken, NJ). 2016.

  2. van Steenbergen HW, van Nies JA, Ruyssen-Witrand A, Huizinga TW, Cantagrel A, Berenbaum F, et al. IL2RA is associated with persistence of rheumatoid arthritis. Arthritis research & therapy. 2015;17:244.

  3. Trellu S, Dadoun S, Berenbaum F, Fautrel B, Gossec L. Intra-articular injections in thumb osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Joint, bone, spine : revue du rhumatisme. 2015;82(5):315-9.

  4. Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Annals of the rheumatic diseases. 2015;74(5):843-50.
     
  5. Reginster JY, Reiter-Niesert S, Bruyere O, Berenbaum F, Brandi ML, Branco J, et al. Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis and cartilage. 2015;23(12):2086-93.

  6. Nourissat G, Ornetti P, Berenbaum F, Sellam J, Richette P, Chevalier X. Does platelet-rich plasma deserve a role in the treatment of tendinopathy? Joint, bone, spine : revue du rhumatisme. 2015;82(4):230-4.

  7. Nourissat G, Berenbaum F, Duprez D. Tendon injury: from biology to tendon repair. Nature reviews Rheumatology. 2015;11(4):223-33.

  8. Nocturne G, Pavy S, Boudaoud S, Seror R, Goupille P, Chanson P, et al. Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. PloS one. 2015;10(8):e0134974.

  9. Nefla M, Sudre L, Denat G, Priam S, Andre-Leroux G, Berenbaum F, et al. The pro-inflammatory cytokine 14-3-3epsilon is a ligand of CD13 in cartilage. Journal of cell science. 2015;128(17):3250-62.

  10. Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD open. 2015;1(1):e000077.

  11. Louati K, Berenbaum F. Fatigue in chronic inflammation – a link to pain pathways. Arthritis research & therapy. 2015;17:254.

  12. Laiguillon MC, Courties A, Houard X, Auclair M, Sautet A, Capeau J, et al. Characterization of diabetic osteoarthritic cartilage and role of high glucose environment on chondrocyte activation: toward pathophysiological delineation of diabetes mellitus-related osteoarthritis. Osteoarthritis and cartilage. 2015;23(9):1513-22.

  13. Gossec L, Saraux A, Hudry C, Mathoret-Philibert F, Poussiere M, de Chalus T, et al. Development and Validation of a Questionnaire Assessing the fears and Beliefs of Patients Suffering from Chronic Rheumatic Diseases. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A708.

  14. Gossec L, Chauvin P, Hudry C, Mathoret-Philibert F, Poussiere M, de Chalus T, et al. The Most Frequent Fears and Beliefs of 226 Patients with Rheumatoid Arthritis or Spondyloarthritis, Using a Novel Questionnaire. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A715.

  15. Goldring MB, Berenbaum F. Emerging targets in osteoarthritis therapy. Current opinion in pharmacology. 2015;22:51-63.

  16. Gherghe AM, Dougados M, Combe B, Landewe R, Mihai C, Berenbaum F, et al. Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD open. 2015;1(1):e000128.

  17. Dougados M, Soubrier M, Perrodeau E, Gossec L, Fayet F, Gilson M, et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Annals of the rheumatic diseases. 2015;74(9):1725-33.

  18. Dougados M, Etcheto A, Molto A, Alonso S, Bouvet S, Daures JP, et al. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. Joint, bone, spine : revue du rhumatisme. 2015;82(5):345-51.

  19. Depont F, Berenbaum F, Filippi J, Le Maitre M, Nataf H, Paul C, et al. Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. PloS one. 2015;10(12):e0145076.

  20. Deligne C, Casulli S, Pigenet A, Bougault C, Campillo-Gimenez L, Nourissat G, et al. Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients. Osteoarthritis and cartilage. 2015;23(11):1843-52.

  21. Cutolo M, Berenbaum F, Hochberg M, Punzi L, Reginster JY. Commentary on recent therapeutic guidelines for osteoarthritis. Seminars in arthritis and rheumatism. 2015;44(6):611-7.

  22. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis and cartilage. 2015;23(11):1955-65..
     
  23. Bruyere O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs & aging. 2015;32(3):179-87.

  24. Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet (London, England). 2015;385(9971):875-82.

  25. Berenbaum F, van den Berg WB. Inflammation in osteoarthritis: changing views. Osteoarthritis and cartilage. 2015;23(11):1823-4.

  26. Arden N, Richette P, Cooper C, Bruyere O, Abadie E, Branco J, et al. Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs & aging. 2015;32(7):525-35.

2014

  1. Souberbielle JC, Benhamou CL, Cortet B, Rousiere M, Roux C, Abitbol V, et al. [Weakening osteopathies, chronic kidney disease, malabsorption, biological anomalies of calium/phosphorus metabolism: appropriate indications for a reasoned reimbursment of serum vitamin D measurement]. Annales de biologie clinique. 2014;72(4):385-9.

  2. Sellam J, Fellahi S, Bastard JP, Capeau J, Berenbaum F. Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’ – authors’ reply. Arthritis research & therapy. 2014;16(2):408.

  3. Pecchi E, Priam S, Gosset M, Pigenet A, Sudre L, Laiguillon MC, et al. Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis research & therapy. 2014;16(1):R16.

  4. Peake NJ, Hobbs AJ, Pingguan-Murphy B, Salter DM, Berenbaum F, Chowdhury TT. Role of C-type natriuretic peptide signalling in maintaining cartilage and bone function. Osteoarthritis and cartilage. 2014;22(11):1800-7.

  5. Mladenovic Z, Saurel AS, Berenbaum F, Jacques C. Potential role of hyaluronic acid on bone in osteoarthritis: matrix metalloproteinases, aggrecanases, and RANKL expression are partially prevented by hyaluronic acid in interleukin 1-stimulated osteoblasts. The Journal of rheumatology. 2014;41(5):945-54.
     
  6. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and cartilage. 2014;22(3):363-88.
     
  7. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. Response to Letter to the Editor entitled “Comments on ‘OARSI guidelines for the non-surgical management of knee osteoarthritis'”. Osteoarthritis and cartilage. 2014;22(6):890-1.

  8. Laiguillon MC, Houard X, Bougault C, Gosset M, Nourissat G, Sautet A, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis research & therapy. 2014;16(1):R38.
     
  9. Hiligsmann M, Cooper C, Guillemin F, Hochberg MC, Tugwell P, Arden N, et al. A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in arthritis and rheumatism. 2014;44(3):271-82.

  10. Gossec L, Berenbaum F, Chauvin P, Lamiraud K, Russo-Marie F, Joubert JM, et al. Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review. Rheumatology (Oxford, England). 2014;53(7):1274-81.

  11. Eymard F, Pigenet A, Citadelle D, Flouzat-Lachaniette CH, Poignard A, Benelli C, et al. Induction of an inflammatory and prodegradative phenotype in autologous fibroblast-like synoviocytes by the infrapatellar fat pad from patients with knee osteoarthritis. Arthritis & rheumatology (Hoboken, NJ). 2014;66(8):2165-74.

  12. Dougados M, Wood E, Combe B, Schaeverbeke T, Miceli-Richard C, Berenbaum F, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis research & therapy. 2014;16(6):481.

  13. Dadoun S, Guillemin F, Lucier S, Looten V, Saraux A, Berenbaum F, et al. Work productivity loss in early arthritis during the first 3 years of disease: a study from a French National Multicenter Cohort. Arthritis care & research. 2014;66(9):1310-8.

  14. Courties A, Guegan S, Miquel A, Duriez P, Berenbaum F, Sellam J. Fibroblastic rheumatism: immunosuppressive therapy is not always required. Joint, bone, spine : revue du rhumatisme. 2014;81(2):178-9.

  15. Bougault C, Priam S, Houard X, Pigenet A, Sudre L, Lories RJ, et al. Protective role of frizzled-related protein B on matrix metalloproteinase induction in mouse chondrocytes. Arthritis research & therapy. 2014;16(4):R137.
     
  16. Berenbaum F, Chauvin P, Hudry C, Mathoret-Philibert F, Poussiere M, De Chalus T, et al. Fears and beliefs in rheumatoid arthritis and spondyloarthritis: a qualitative study. PloS one. 2014;9(12):e114350.
     
  17. Berenbaum F. The social (media) side to rheumatology. Nature reviews Rheumatology. 2014;10(5):314-8.

  18. Berenbaum F. Does broccoli protect from osteoarthritis? Joint, bone, spine : revue du rhumatisme. 2014;81(4):284-6.

  19. Aouizerate J, De Antonio M, Bassez G, Gherardi RK, Berenbaum F, Guillevin L, et al. Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta neuropathologica communications. 2014;2:154.

2013

  1. Sellam J, Kotti S, Fellahi S, Bastard JP, Meyer M, Lioté F, Meyer O, Simon T, Capeau J, Berenbaum F.    Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. Annals of the Rheumatic Diseases 
                  
  2. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis and Cartilage            
                                                                                                            
  3. Le Boedec M, Jousse-Joulin S, Ferlet JF, Marhadour T, Chales G, Grange L, Hacquard-Bouder C, Loeuille D, Sellam J, Albert JD, Bentin J, Chary-Valckenaere I, D’Agostino MA, Etchepare F, Gaudin P, Hudry C, Dougados M, Saraux A.                Factors influencing concordance between clinical and ultrasound findings in rheumatoid arthritis. Journal of Rheumatology                 
                                                                                    
  4. Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, Sibilia J, Bourgeois P, Fautrel B; CRI (Club Rhumatismes et Inflammation). Anakinra in Adult-Onset Still’s Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy.  Arthritis Care and Research                   
                                                                 
  5. Godot S, Gottenberg J-E, Paternotte S, Pane I, Combe B,. Sibilia J, Flipo R-M, Schaeverbeke T, Ravaud P, Toussirot E, Berenbaum F, Mariette X, Wendling D, Sellam J.             Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the AutoImmunity and Rituximab registry. Arthritis Care and Research 
             
  6. Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Le Loët X, Tebib J, Jourdan R, Dougados M, Taoufik, Y, Mariette X            CCL19, a B-cell related chemokine, is related to the decrease of blood memory B-cells and predicts the clinical response to rituximab in rheumatoid arthritis. Arthritis and Rheumatism (AO)
  7. Priam S, Bougault C, Houard X, Gosset M, Salvat C, Berenbaum F, Jacques C.    Identification of soluble 14-3-3? as a new subchondral bone mediator involved in cartilage degradation in osteoarthritis.     Arthritis and Rheumatism
  8. Schett G, Kleyer A, Perricone C, Sahinbegovic E, Iagnocco A, Zwerina J, Lorenzini R, Aschenbrenner F, Berenbaum F, D’Agostino MA, Willeit J, Kiechl S.           Diabetes Is an Independent Predictor for Severe Osteoarthritis: Results from a longitudinal cohort study.           Diabetes Care  
  9. Saraux A, Tobón GJ, Benhamou M, Devauchelle-Pensec V, Dougados M, Mariette X, Berenbaum F, Chiocchia G, Rat AC, Schaeverbeke T, Rincheval N, Fautrel B, Combe B. Potential classification criteria for rheumatoid arthritis after two years: Results from a French multicenter cohort.  Arthritis Care and Research             
                                                                                
  10. Cooper C, Adachi JD, Bardin T, Berenbaum F, Flamion B, Jonsson H, Kanis JA, Pelousse F, Lems WF, Pelletier JP, Martel-Pelletier J, Reiter S, Reginster JY, Rizzoli R, Bruyère O.   How to define responders in osteoarthritis.Curr Med Res Opin            
             
  11. Berenbaum F    Osteoarthritis: when chondrocytes don’t wake up on time. Arthritis and Rheumatism
  12. Marie-Justine Guerquin, Benjamin Charvet, Geoffroy Nourissat, Emmanuelle Havis, Olivier Ronsin, Marie-Ange Bonnin, Mathilde Ruggiu, Isabel Olivera-Martinez, Nicolas Robert, Yinhui Lu, Karl E. Kadler, Tristan Baumberger,Levon Doursounian, Francis Berenbaum, Delphine Duprez      Egr1 directs tendon differentiation and promotes tendon repair. Journal of Clinical Investigation  

2012

 

  1. Jacques C, Holzenberger M, Mladenovic Z, Salvat C, Pecchi E, Berenbaum F, Gosset M. Pro-inflammatory actions of visfatin/Nampt involve regulation of insulin signaling pathway and Nampt enzymatic activity. J Biol Chem. 2012 Apr 27;287(18):15100-8.
  2. Hodkinson B, Maheu E, Michon M, Carrat F, Berenbaum F. Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Ann Rheum Dis. 2012 Jan;71(1):45-9. Epub 2011 Sep 6.
  3. Pecchi E, Priam S, Mladenovic Z, Gosset M, Saurel AS, Aguilar L, Berenbaum F, Jacques C.  A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1?-stimulated osteoblasts.Osteoarthritis Cartilage. 2012 Feb;20(2):127-35. Epub 2011 Dec 11.
  4. Chauffier K, Laiguillon MC, Bougault C, Gosset M, Priam S, Salvat C, Mladenovic Z, Nourissat G, Jacques C, Houard X, Berenbaum F, Sellam J. Induction of the chemokine IL-8/Kc by the articular cartilage: Possible influence on osteoarthritis.Joint Bone Spine. 2012 Feb 15. [Epub ahead of print]
  5. Berenbaum F, Grifka J, Cazzaniga S, D’Amato M, Giacovelli G, Chevalier X, Rannou F, Rovati LC, Maheu E.A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis.Ann Rheum Dis. 2012 Jan 31.
  6. Fautrel B, Combe B, Rincheval N, Dougados M; ESPOIR Scientific Committee.Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data.Ann Rheum Dis. 2012 Mar;71(3):386-9. Epub 2011 Oct 28.
  7. Chauffier K, Salliot C, Berenbaum F, Sellam J.Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis.Rheumatology(Oxford). 2012 Jan;51(1):60-8. Epub 2011 Apr 22.
  8. Pham T, Berthelot JM, Blacher J, Constantin A, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Lequerré T, Marolleau JP, Martinez V, Masson C, Mouthon L, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Sellam J, Soubrier M, VittecoqO, Wendling D, Mariette X, Sibilia J. Prise en charge pratique des patients sous rituximab. Fiches pratiques élaborées par le Club Rhumatismes et Inflammation (CRI), mise à jour 2012. Rev Rhum, 2012,
  9. Kemta Lekpa F, Poulain C, Wendling D, Soubrier M, De Bandt M, Berthelot JM, Gaudin P, Toussirot E, Goupille P, Pham T, Sellam J, Bruckert R, Paul M, Farrenq V, Claudepierre P, on behalf of the Club Rhumatismes et Inflammations.Is interleukin-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multi-center retrospective observational study. Arthritis Res Ther 2012, 9;14(2):R53
  10. Puéchal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, Morel J, Wendling D, de Bandt M, Houvenagel E, Jamard B, Lequerr T, Morel G, Richette P, Sellam J, Guillevin L, Mariette X; on Behalf of the Investigators of the AutoImmunity and Rituximab registry. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis. Results from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 2012 64(3):331-9
  11. Berenbaum F.Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype.Postgrad Med J. 2012 Apr;88(1038):240-2.
  12. Majhoub M, Berenbaum F, Houard X. Why subchondral bone in osteoarthritis ? The importance of the cartilage bone interface in osteoarthritis.O steoporosis Int. Sous presse.
  13. Sellam J, Berenbaum F. Osteoarthritis and obesity.Rev Praticien 2012 May;62(5):621-4
  14. Sellam J, Berenbaum F. When to refer a patient with osteoarthritis to the surgeon ?.Rev Praticien 2012 May;62(5):644-647

2011

1. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Chauffier K, Salliot C, Berenbaum F, Sellam J. Rheumatology (Oxford). 2011 Apr 22. [Epub ahead of print] PMID: 21515629 [PubMed – as supplied by publisher] Related citations Remove from clipboard 

2. Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Berenbaum F. Ann Rheum Dis. 2011 Apr 6. [Epub ahead of print] PMID: 21474484 [PubMed – as supplied by publisher] Related citations Remove from clipboard

3. The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. Dougados M, d’Agostino MA, Benessiano J, Berenbaum F, Breban M, Claudepierre P, Combe B, Dargent-Molina P, Daurès JP, Fautrel B, Feydy A, Goupille P, Leblanc V, Logeart I, Pham T, Richette P, Roux C, Rudwaleit M, Saraux A, Treluyer JM, van der Heijde D, Wendling D. Joint Bone Spine. 2011 Mar 30. [Epub ahead of print] PMID: 21458351 [PubMed – as supplied by publisher] Related citations Remove from clipboard

4. Assessing health-related quality of life in hand osteoarthritis: a literature review. Michon M, Maheu E, Berenbaum F. Ann Rheum Dis. 2011 Jun;70(6):921-8. Epub 2011 Mar 11. PMID: 21398333 [PubMed – in process] Related citations Remove from clipboard

5. Introduction to OARSI FDA initiative OAC special edition. Abramson SB, Berenbaum F, Hochberg MC, Moskowitz RW. Osteoarthritis Cartilage. 2011 Mar 23. [Epub ahead of print] No abstract available. PMID: 21396473 [PubMed – as supplied by publisher] Related citations Remove from clipboard

6. Osteoarthritis year 2010 in review: pharmacological therapies. Berenbaum F. Osteoarthritis Cartilage. 2011 Apr;19(4):361-5. Epub 2011 Feb 12. PMID: 21320615 [PubMed – in process] Related citations Remove from clipboard

7. Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B. J Rheumatol. 2011 May;38(5):835-45. Epub 2011 Jan 15. PMID: 21239748 [PubMed – in process] Related citations Remove from clipboard

8. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.

2010

  1. Rannou F, Sellam J, Berenbaum F.Pathophysiology of osteoarthritis: updated concepts. Presse Med. 2010 Nov;39(11):1159-63.

  2. Gosset M, Pigenet A, Salvat C, Berenbaum F, Jacques C.Inhibition of matrix metalloproteinase-3 and -13 synthesis induced by IL-1beta in chondrocytes from mice lacking microsomal prostaglandin E synthase-1. J Immunol2010 Nov 15;185(10):6244-52.

  3. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010 Nov;6(11):625-35.

  4. Berenbaum F. The OARSI histopathology initiative – the tasks and limitations. Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S1.

  5. Nourissat G, Diop A, Maurel N, Salvat C, Dumont S, Pigenet A, Gosset M, Houard X, Berenbaum F. Mesenchymal stem cell therapy regenerates the native bone-tendon junction after surgical repair in a degenerative rat model. PLoS One. 2010 Aug 18;5(8):e12248.

  6. Berenbaum F. Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov. Best Pract Res Clin Rheumatol. 2010 Feb;24(1):107-19.

  7. Berenbaum F. Osteoarthritis. Preface. Best Pract Res Clin Rheumatol. 2010 Feb;24(1):1-2.

  8. Fautrel B, Benhamou M, Foltz V, Rincheval N, Rat AC, Combe B, Berenbaum F, Bourgeois P, Guillemin F. Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. Rheumatology (Oxford). 2010 Jan;49(1):147-55.

  9. Gabay O, Sanchez C, Salvat C, Chevy F, Breton M, Nourissat G, Wolf C,Jacques C, Berenbaum F. Stigmasterol: a phytosterol with potential anti-osteoarthritic properties. Osteoarthritis Cartilage. 2010 Jan;18(1):106-16.

  10. Nchimi A, Defawe O, Brisbois D, Broussaud TK, Defraigne JO, Magotteaux P, Massart B, Serfaty JM, Houard X, Michel JB, Sakalihasan N. MR imaging of iron
    phagocytosis in intraluminal thrombi of abdominal aortic aneurysms in humans.
     Radiology. 2010 Mar;254(3):973-81.

  11. Coutard M, Touat Z, Houard X, Leclercq A, Michel JB. Thrombus versus wall biological activities in experimental aortic aneurysms. J Vasc Res.2010;47(4):355-66.

  12. Le Dall J, Ho-Tin-Noé B, Louedec L, Meilhac O, Roncal C, Carmeliet P, Germain S, Michel JB, Houard X. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors.Cardiovasc Res. 2010 Jan 1;85(1):184-93..

  13. Marhadour T, Jousse-Joulin S, Chalès G, Grange L, Hacquard C, Loeuille D,Sellam J, Albert JD, Bentin J, Chary Valckenaere I, d’Agostino MA, Etchepare F, Gaudin P, Hudry C, Dougados M, Saraux A. Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on Disease Activity Score-28 values (SEA-Repro study part I). J Rheumatol2010 May;37(5):932-7.

  14. Jousse-Joulin S, d’Agostino MA, Marhadour T, Albert JD, Bentin J, Chary Valckenaere I, Etchepare F, Gaudin P, Hudry C, Chalès G, Grange L, Hacquard C, Loeuille D, Sellam J, Dougados M, Saraux A. Reproducibility of joint swelling assessment by sonography in patients with long-lasting rheumatoid arthritis (SEA-Repro study part II). J Rheumatol. 2010 May;37(5):938-45.

  15. Nocturne G, Dougados M, Constantin A, Richez C, Sellam J, Simon A, Wendling D, Mariette X, Gottenberg JE. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis. 2010 Feb;69(2):471-2.